The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $3.47 in the prior trading day, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $3.40, down -2.02%. In other words, the price has decreased by $-2.02 from its previous closing price. On the day, 1.79 million shares were traded. ALLO stock price reached its highest trading level at $3.63 during the session, while it also had its lowest trading level at $3.38.
Ratios:
Our goal is to gain a better understanding of ALLO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.58 and its Current Ratio is at 12.58. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On December 08, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $7.Citigroup initiated its Buy rating on December 08, 2023, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 30 ’24 when Parker Geoffrey M. bought 190 shares for $3.60 per share. The transaction valued at 683 led to the insider holds 819,590 shares of the business.
MESSEMER DEBORAH M. sold 18,640 shares of ALLO for $50,317 on Dec 18 ’23. The Director now owns 62,456 shares after completing the transaction at $2.70 per share. On Aug 07 ’23, another insider, Mayo Stephen, who serves as the Director of the company, sold 10,000 shares for $4.29 each. As a result, the insider received 42,855 and left with 25,328 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 574912832 and an Enterprise Value of 233173216. For the stock, the TTM Price-to-Sale (P/S) ratio is 3593.16 while its Price-to-Book (P/B) ratio in mrq is 0.98. Its current Enterprise Value per Revenue stands at 2454.455 whereas that against EBITDA is -0.776.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $6.89, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is -24.14%, while the 200-Day Moving Average is calculated to be -10.21%.
Shares Statistics:
The stock has traded on average 2.33M shares per day over the past 3-months and 1926720 shares per day over the last 10 days, according to various share statistics. A total of 169.09M shares are outstanding, with a floating share count of 104.72M. Insiders hold about 38.07% of the company’s shares, while institutions hold 60.84% stake in the company. Shares short for ALLO as of 1711584000 were 30621417 with a Short Ratio of 13.13, compared to 1709164800 on 25007919. Therefore, it implies a Short% of Shares Outstanding of 30621417 and a Short% of Float of 26.6.
Earnings Estimates
A comprehensive evaluation of Allogene Therapeutics Inc (ALLO) is underway, with the input of European Union Allowance (EUA) analysts contributing to its current rating.The consensus estimate for the next quarter is $175.41, with high estimates of $1.90 and low estimates of $39.74.
